Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023. This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD. Daneshmand ...

NEW ORLEANS -- Add-On IL15RaFc superagonist N-803 (VesAnktiva) to Bacillus Calmette-Guérin (BCG) treatment led to "a clinically meaningful benefit" in BCG-unresponsive non-muscle invasive bladder ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Novel immunotherapies and chemotherapies hold promise as non-surgical salvage options. Recent advances in our understanding of systemic immunotherapy, however, have transformed the management of ...

What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...

The bacillus Calmette-Guérin (BCG) vaccine nearly halved the risk of progression among patients with non–muscle invasive bladder cancer (NMIBC) compared with transurethral resection of the bladder ...

Instead, he chose to be the first person in Texas to try Inlexzo. Inlexzo is a chemotherapy that comes in a tube that looks ...

Scientists at Memorial Sloan Kettering have found that BCG, a commonly used immunotherapy for bladder cancer, works differently than many researchers had assumed. For people with early-stage bladder ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...